Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, Benzamide Riboside, in human myelogenous leukemia K562 cells

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 5, 1996, Pages 278-285

  Jayaram, H N ^a   O'Connor, A ^a   Grant, M R ^a   Yang, H ^a   Grieco, P A ^b   Cooney, D A ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Benzamide riboside; Biochemical mechanisms of resistance; Drug resistance; Human myelogenous leukemia K562 cells; IMP dehydrogenase inhibitor; NAD analogue

Indexed keywords

3 (1 DEOXYRIBOFURANOSYL)BENZAMIDE; 3-(1-DEOXYRIBOFURANOSYL)BENZAMIDE; ENZYME INHIBITOR; INOSINATE DEHYDROGENASE; NUCLEOSIDE; NUCLEOTIDYLTRANSFERASE; RIBONUCLEOTIDE;

ADULT; ARTICLE; CELL LINE; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG RESISTANCE; HUMAN; METABOLISM; PATHOLOGY;

ADULT; CELL LINE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; IMP DEHYDROGENASE; LEUKEMIA, MYELOID, CHRONIC; NUCLEOSIDES; NUCLEOTIDYLTRANSFERASES; RIBONUCLEOTIDES;

EID: 0030223265     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Robins RK, Srivastava PC, Narayanan VL, Plowman J, Paull KD. 2-β-D-Ribofuranosylthiazole-4-carboxamide, a novel potential anti-tumor agent for lung tumors and metastases. J Med Chem 25: 107-108, 1982.
2. Jayaram HN, Dion RL, Glazer RI, Johns DG, Robins RK, Srivastava PC, Cooney DA. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-D-ribofuranosylthiazole-4-carboxamide. Biochem Pharmacol 31: 2371-2380, 1982.
3. Jayaram HN, Smith AL, Glazer RI, Johns DG, Cooney DA. Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 31: 3839-3845, 1982.
4. Earle MF, Glazer RI. Activity and metabolism of 2-β-D-ribofuranosylthiazole-carboxamide in human lymphoid tumor cells in culture. Cancer Res 43: 133-137, 1983.
5. Ahluwalia GS, Jayaram HN, Plowman J, Cooney DA, Johns DG. Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide. V. Factors governing the response of murine tumors to tiazofurin. Drug Metab Dispos 12: 165-173, 1984.
6. Jayaram HN, Ahluwalia GS, Dion RL, et al. Conversion of 2-β-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase inhibitory properties. Biochem Pharmacol 32: 2633-2636, 1983.
7. Jayaram HN, Gharehbaghi K, Jayaram NH, Rieser J, Krohn K, Paull KD. Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells. Biochem Biophys Res Commun 186: 1600-1606, 1992.
8. Gharehbaghi K, Paull KD, Kelley JA, et al. Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase. Int J Cancer 56: 892-899, 1994.
9. Gharehbaghi K, Sreenath A, Hao Z, et al. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem Pharmacol 48: 1413-1419, 1994.
10. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE, Johns DG. The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 31: 2133-2136, 1982.
11. Carney DN, Ahluwalia GS, Jayaram HN, Cooney DA, Johns DG. Relationship between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells. J Clin Invest 75: 175-182, 1985.
12. Cooney DA, Wilson Y, McGee E. A straightforward and radiometric technique for measuring IMP dehydrogenase. Anal Biochem 130: 339-345, 1983.
13. Jayaram HN, Zhen W, Gharehbaghi K. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemia K562 cells. Cancer Res 53: 2344-2348, 1993.
14. Paulik E, Jayaram HN, Weber G. Determination of NAD pyrophosphorylase activity in biological samples. Anal Biochem 197: 143-148, 1991.
15. Zhen W, Jayaram HN, Weber G. Determination of TAD (thiazole-4-carboxamide adenine dinucleotide) levels in mononuclear cells of leukemic patients treated with tiazofurin. Biochem Pharmacol 41: 281-286, 1991.
16. Yamada Y, Goto H, Yoshino M, Ogasawara N. IMP dehydrogenase and action of antimetabolites in human cultured cells. Biochim Biophys Acta 1051: 209-214, 1990.
17. Krohn K, Heins H, Wielckens K. Synthesis and cytotoxicity of C-glycosidic nicotinamide riboside analogues. J Med Chem 35: 511-517, 1992.
18. Jayaram HN, Pillwein K, Lui MS, Faderan MA, Weber G. Mechanism of resistance to tiazofurin in hepatoma 3924A. Biochem Pharmacol 35: 587-593, 1986.
19. Tricot GJ, Jayaram HN, Nichols CR, Pennington D, Lapis E, Weber G, Hoffman R. Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia. Cancer Res 47: 4988-4991, 1987.
20. Tricot GJ, Jayaram HN, Lapis E, et al. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-monophosphate dehydrogenase activity. Cancer Res 49: 3696-3701, 1989.
21. Jayaram HN, Lapis E, Tricot GJ, et al. Clinical pharmacokinetic study of tiazofurin administered as a 1-hr infusion. Int J Cancer 51: 182-188, 1992.
22. th International Congress of Chemotherapy, Vienna, Part 261, pp. 46-52, 1983.
23. Summarized by Cooney D, Kutzmits R. Pharmacology of anticancer drugs. Cancer Treat Rev 11: 269-274, 1984.